Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860540 | 0.91 | PSMB5 (0.43) | PSMB5CDK1LTB4RLTB4R2 | |
| SCHEMBL9652705 | 0.88 | PSMB5 (0.60) | PSMB5CDK1HSD11B1GPR3RARB | |
| SCHEMBL4860000 | 0.84 | NPC1 (0.47) | LTB4RLTB4R2ALDH1A1 | |
| SCHEMBL9652691 | 0.81 | HSD11B1 (0.45) | PSMB5HSD11B1RARBLTB4R2ALDH1A1 | |
| SCHEMBL11325207 | 0.80 | PSMB5 (0.61) | PSMB5HSD11B1GPR3RARBALDH1A1 | |
| SCHEMBL13454809 | 0.79 | XDH (0.48) | RARBLTB4R2 | |
| SCHEMBL7091136 | 0.79 | CDK1 (0.60) | CDK1RARBTRPV1 | |
| SCHEMBL4861353 | 0.78 | PSMB5 (0.49) | PSMB5CDK1GPR3ALDH1A1HPGD | |
| SCHEMBL7947727 | 0.78 | LTB4R (0.58) | GPR3RARBLTB4RLTB4R2ALDH1A1 | |
| SCHEMBL28679637 | 0.77 | PSMB5 (0.51) | PSMB5HSD11B1GPR3RARBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405331-B2 | High-purity (fluoroalkyl)benzene derivative and process for producing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-07-29 | — | — | US | disclosed |
| US-20060167324-A1 | High-purity (fluoroalkyl)benzene derivative and process for producing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1500641-A1 | HIGH-PURITY (FLUOROALKYL)BENZENE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167324-A1 | High-purity (fluoroalkyl)benzene derivative and process for producing the same | HBB, AFF4, AFF2 | PSMB5 373/4885CDK1 4855/4885HSD11B1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.